Allergan's most recent trend suggests a bullish bias. One trading opportunity on Allergan is a Bull Put Spread using a strike $230.00 short put and a strike $220.00 long put offers a potential 16.14% return on risk over the next 30 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $230.00 by expiration. The full premium credit of $1.39 would be kept by the premium seller. The risk of $8.61 would be incurred if the stock dropped below the $220.00 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Allergan is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Allergan is bullish.
The RSI indicator is above 80 which suggests that the stock is in overbought territory.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Allergan
Allergan Is Putting the Bull Back in Charge
Mon, 19 Jun 2017 18:39:00 +0000
Prices have rallied since late May.
Valeant Pharmaceuticals Intl Inc (VRX) Stock Isn’t Healed by Paulson’s Presence
Mon, 19 Jun 2017 17:47:28 +0000
It remains to be seen if John Paulson’s presence on the board of directors of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) will make a positive difference for the beleaguered company. John Paulson is the chief of hedge fund Paulson & Co., which rose to infamy after making a (very) correct bearish call on the U.S. housing market in 2007.
Could Legalized Marijuana Be Making Big Pharma Nervous?
Sun, 18 Jun 2017 18:03:00 +0000
A new report says that drugmakers could lose billions of dollars per year if marijuana is legalized throughout the U.S. Should Pfizer, Allergan, and others be nervous?
5 Things Allergan's Management Just Said That You Need to Know
Thu, 15 Jun 2017 19:42:00 +0000
Allergan executives hint at what's in store for the drugmaker at the Goldman Sachs healthcare conference.
Allergan CEO on the battle over drug pricing
Thu, 15 Jun 2017 17:38:00 +0000
CNBC's Meg Tirrell talks to Brent Saunders, Allergan CEO, about an executive order on possibly lowering drug prices live from the Heartland Health Summit.
Also on Market Tamer…
Follow Us on Facebook